Palvella Therapeutics, Inc. (NASDAQ:PVLA) Stock Has Average Price Target of $209.14

Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) have received an average rating of “Moderate Buy” from the fifteen analysts that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $209.14.

PVLA has been the subject of several analyst reports. HC Wainwright reiterated a “buy” rating and issued a $270.00 target price on shares of Palvella Therapeutics in a research note on Wednesday, July 22nd. Truist Financial set a $207.00 price objective on shares of Palvella Therapeutics in a report on Wednesday, August 5th. Chardan Capital started coverage on shares of Palvella Therapeutics in a research report on Monday. They issued a “buy” rating and a $240.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Palvella Therapeutics in a research report on Monday, June 29th. Finally, Canaccord Genuity Group set a $232.00 price target on Palvella Therapeutics in a report on Wednesday, August 5th.

Palvella Therapeutics Stock Down 5.4%

Shares of NASDAQ PVLA opened at $138.16 on Friday. The business’s 50 day moving average price is $149.29 and its 200 day moving average price is $133.43. The firm has a market cap of $1.99 billion, a P/E ratio of -28.60 and a beta of -0.25. Palvella Therapeutics has a 52 week low of $58.16 and a 52 week high of $161.38.

Palvella Therapeutics (NASDAQ:PVLA) last issued its earnings results on Tuesday, August 4th. The company reported ($1.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35). As a group, research analysts expect that Palvella Therapeutics will post -6.36 earnings per share for the current year.

Insider Transactions at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $152.21, for a total transaction of $654,807.42. Following the completion of the transaction, the chief operating officer directly owned 2,154 shares of the company’s stock, valued at $327,860.34. This represents a 66.64% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher Kiritsy sold 313 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $157.00, for a total value of $49,141.00. Following the transaction, the director owned 250 shares in the company, valued at $39,250. This trade represents a 55.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 36,417 shares of company stock valued at $5,526,138 in the last three months. 17.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Palvella Therapeutics

Several large investors have recently bought and sold shares of PVLA. KBC Group NV acquired a new position in shares of Palvella Therapeutics during the 1st quarter worth approximately $28,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Palvella Therapeutics in the second quarter valued at approximately $35,000. Archer Investment Corp purchased a new position in Palvella Therapeutics during the second quarter worth approximately $69,000. Quantbot Technologies LP purchased a new position in Palvella Therapeutics during the second quarter worth approximately $71,000. Finally, State of Wyoming acquired a new position in Palvella Therapeutics during the second quarter worth $134,000. 40.11% of the stock is currently owned by hedge funds and other institutional investors.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for patients with rare genetic and dermatologic diseases. The company uses its proprietary QTORIN platform to formulate and deliver medicines locally to affected tissues, with the goal of improving treatment effectiveness while limiting systemic exposure.

Palvella’s lead program is QTORIN 3.9% rapamycin, an investigational topical gel being developed for microcystic lymphatic malformations, rare lesions caused by abnormalities in the lymphatic system.